3′-18F-fluoro-3′-deoxy-L-thymidine: A new tracer for staging metastatic melanoma?

Journal of Nuclear Medicine

Volumn 44, Issue 12, 2003, Pages 1927-1932

  Cobben, David C P ^a   Jager, Piet L ^a   Elsinga, Philip H ^a   Maas, Bram ^a   Suurmeijer, Albert J H ^a   Hoekstra, Harald J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

3 18F fluoro 3 deoxy L thymidine; Melanoma; PET; Staging

Indexed keywords

2',3' DIDEOXYTHYMIDINE F 18; FLUORINE 18; LACTATE DEHYDROGENASE; TRACER; UNCLASSIFIED DRUG; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME ASSAY; HISTOPATHOLOGY; HUMAN; IMAGING SYSTEM; LYMPH NODE METASTASIS; MELANOMA; METASTASIS; MITOSIS; PATIENT SELECTION; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; SCORING SYSTEM; SENSITIVITY ANALYSIS; THORAX RADIOGRAPHY; ULTRASOUND; ADULT; AGED; BONE MARROW CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEASIBILITY STUDY; FEMALE; LABORATORY DIAGNOSIS; LIVER TUMOR; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SKIN TUMOR;

ADULT; AGED; BONE MARROW NEOPLASMS; DIDEOXYNUCLEOSIDES; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEASIBILITY STUDIES; FEMALE; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 1542682069     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. 18F-FDG in oncology. J Nucl Med Technol 2002;30:3-9.
2. Herholz K. Rudolf J, Heiss WD. FDG transport and phosphorylation in human gliomas measured with dynamic PET. J Neurooncol. 1992;12:159-165.
3. Som P, Atkins HL. Bandoypadhyay D, et al. A fluorinated glucose analog. 2-fluoro-2-deoxy-D-glucose (F-18). nontoxic tracer for rapid tumor detection. J Nucl Med. 1980;21:670-675.
4. 18F-2-Deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. feasibility studies for cancer imaging with positron-emission tomography. Cancer 1991;67:1544-1550.
5. Cobben DC, Koopal S, Tiebosch AT, et al. New diagnostic techniques in staging in the surgical treatment of cutaneous malignant melanoma. Eur J Surg Oncol. 2002;28:692-700.
6. Gershenwald JE, Thompson W, Mansfield PF, et al Multi-institutional melanoma lymphatic mapping experience the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients J Clin Oncol. 1999;17:976-983.
7. Morton DL, Wen DR, Wong JH, et al Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-399.
8. Morton DL, Thompson JF, Essner R, et al Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial - Multicenter Selective Lymphadenectomy Trial Group. Ann Surg. 1999;230:453-463.
9. 18FDG PET imaging versus sentinel node detection Oncologist. 2002;7:271-278.
10. Tyler DS, Onaitis M, Kherani A, et al. Positron emission tomography scanning in malignant melanoma. Cancer. 2000;89:1019-1025.
11. Wagner JD, Schauwecker DS, Davidson D, Wenck S, Jung SH, Hutchins G. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol. 2001;77:237-242.
12. Schwimmer J, Essner R, Patel A, et al. A review of the literature for whole-body FDG PET in the management of patients with melanoma Q J Nucl Med. 2000;44:153-167.
13. 18F-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer 2001;91:1530-1542.
14. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo. high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.
15. Yamada Y, Uchida Y, Tatsumi K, et al. Fluorine-18-fluorodeoxyglucose and carbon-11-methionme evaluation of lymphadenopathy in sarcoidosis J Nucl Med. 1998;39:1160-1166.
16. Langen KJ, Braun U, Rota KE, et al The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas J Nucl Med. 1993;34:355-359.
17. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336.
18. Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem 1988;263:8350-8358.
19. 18F]FLT) J Radiochem Nucl Chem. 2000;243:843-846.
20. Schelbert HR, Hoh CK, Royal HD, et al. Procedure guideline for tumor imaging using fluorine-18-FDG. J Nucl Med. 1998;39:1302-1305.
21. Lonneux M, Borbath I, Bol A, et al. Attenuation correction in whole-body FDG oncological studies: the role of statistical reconstruction. Eur J Nucl Med. 1999;26:591-598.
22. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648.
23. Wagner JD, Schauwecker D, Davidson D, et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol. 1999;17: 1508-1515.
24. Mijnhout GS, Hoekstra OS, Van Lingen A, et al. How morphometric analysis of metastatic load predicts the (un)usefulness of PET scanning: the case of lymph node staging in melanoma. J Clin Pathol. 2003;56:283-286.
25. 18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol. 1998;16:1770-1776.
26. Acland KM, Healy C, Calonje E, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol. 2001;19:2674-2678.
27. Crippa F, Leutner M, Belli F, et al. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med. 2000;41:1491-1494.
28. Prichard RS, Hill AD, Skehan SJ, O'Higgins NJ. Positron emission tomography for staging and management of malignant melanoma. Br J Surg. 2002;89:389-396.
29. Stas M, Stroobants S, Dupont P, et al. 18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact. Melanoma Res 2002;12:479-490.
30. 18F]FLT-PET in brain tumors [abstract]. J Nucl Med. 2000;41(suppl):216P.
31. 18F-FLT-PET to assess the metabolic activity of primary and metastatic brain tumors [abstract]. J Nucl Med. 2002,43(suppl).111P.